Reminder: Weekly scheduled exchange maintenance will occur from 3-5 AM ET. Trading will be paused during this time.

Biotech

MARKETS INVEST LIVE108

Biotech

FDA decision: BBP-418 by Ml Bio Solutions Inc. (this year)

Yes

1.06x

No

7.25x

$869 vol

FDA decision: Venglustat by Sanofi (this year)

Yes

1.15x

No

4.31x

$968 vol

FDA decision: Vamikibart by Genentech (on or before July 31, 2027)

Yes

1.01x

No

1.01x

$0 vol

FDA decision: Ulixacaltamide by Praxis Precision Medicines (on or before January 29, 2027)

Yes

1.01x

No

1.01x

$0 vol

FDA decision: Tozorakimab by AstraZeneca (on or before March 31, 2027)

Yes

1.01x

No

1.01x

$0 vol

FDA decision: Saroglitazar by Zydus Therapeutics (this year)

Yes

1.31x

No

2.89x

$1,309 vol

FDA decision: Ralinepag by United Therapeutics (on or before June 24, 2027)

Yes

1.01x

No

1.01x

$0 vol

FDA decision: Lorundrostat by Mineralys Therapeutics (on or before December 22, 2026)

Yes

1.01x

No

1.01x

$0 vol

FDA decision: Ivonescimab by Summit Therapeutics (this year)

Yes

1.93x

No

1.62x

$9,185 vol

FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (this year)

Yes

1.04x

No

7.85x

$4,057 vol

FDA decision: BBP-418 by Ml Bio Solutions Inc. (this year)

Yes

1.06x

No

7.25x

$869 vol

FDA decision: Venglustat by Sanofi (this year)

Yes

1.15x

No

4.31x

$968 vol

FDA decision: Vamikibart by Genentech (on or before July 31, 2027)

Yes

1.01x

No

1.01x

$0 vol

FDA decision: Ulixacaltamide by Praxis Precision Medicines (on or before January 29, 2027)

Yes

1.01x

No

1.01x

$0 vol

FDA decision: Tozorakimab by AstraZeneca (on or before March 31, 2027)

Yes

1.01x

No

1.01x

$0 vol

FDA decision: Saroglitazar by Zydus Therapeutics (this year)

Yes

1.31x

No

2.89x

$1,309 vol

FDA decision: Ralinepag by United Therapeutics (on or before June 24, 2027)

Yes

1.01x

No

1.01x

$0 vol

FDA decision: Lorundrostat by Mineralys Therapeutics (on or before December 22, 2026)

Yes

1.01x

No

1.01x

$0 vol

FDA decision: Ivonescimab by Summit Therapeutics (this year)

Yes

1.93x

No

1.62x

$9,185 vol

FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (this year)

Yes

1.04x

No

7.85x

$4,057 vol

Finance

Finance

Biotech

Biotech

FDA decision: BBP-418 by Ml Bio Solutions Inc. (this year)

FDA decision: Venglustat by Sanofi (this year)

FDA decision: Vamikibart by Genentech (on or before July 31, 2027)

FDA decision: Ulixacaltamide by Praxis Precision Medicines (on or before January 29, 2027)

FDA decision: Tozorakimab by AstraZeneca (on or before March 31, 2027)

FDA decision: Saroglitazar by Zydus Therapeutics (this year)

FDA decision: Ralinepag by United Therapeutics (on or before June 24, 2027)

FDA decision: Lorundrostat by Mineralys Therapeutics (on or before December 22, 2026)

FDA decision: Ivonescimab by Summit Therapeutics (this year)

FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (this year)

FDA decision: BBP-418 by Ml Bio Solutions Inc. (this year)

FDA decision: Venglustat by Sanofi (this year)

FDA decision: Vamikibart by Genentech (on or before July 31, 2027)

FDA decision: Ulixacaltamide by Praxis Precision Medicines (on or before January 29, 2027)

FDA decision: Tozorakimab by AstraZeneca (on or before March 31, 2027)

FDA decision: Saroglitazar by Zydus Therapeutics (this year)

FDA decision: Ralinepag by United Therapeutics (on or before June 24, 2027)

FDA decision: Lorundrostat by Mineralys Therapeutics (on or before December 22, 2026)

FDA decision: Ivonescimab by Summit Therapeutics (this year)

FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (this year)